Idogen AB, a Ventac portfolio company, announces allowance/grant of a patent application, covering the company’s tolerogenic vaccine technology in Japan, Europe and the US. For more information, please follow this link.
We participate in numerous events promoting our portfolio companies and meeting our clients.
Ventac Partners invest in Neuroscience Technologies to acquire significant co-ownership, and has deployed its international team to the company to grow the business. Neuroscience Technologies is a global leader in human pain neurophysiology. Employing microneurography technology developed over the last decade, Neuroscience Technologies has successfully provided services to the pharmaceutical industry with pre-clinical and clinical services in neuropathic pain and other peripheral nervous disorders quantifying spontaneous activity in pain fibers. For more information on Neuroscience Technologies, visit www.nsc-tec.com.
Idogen AB, a Ventac portfolio company, announced that the European Commission has granted an orphan drug designation to Idogen’s treatment approach in patients with hemophilia. For more information, please follow this link.
RhoVac AB, a Ventac portfolio company, announced that the Danish Medicines Agency and the Ethics Committee issued their respective approvals to RhoVac’s application to initiate its first clinical study. The planned phase I / II trial will be an open study including approximately 20 patients diagnosed with metastatic cancer. For more information, please follow this link (in Swedish).